Calcium and vitamin D supplements improves bone health after menopause
Tweet Washington, June 27 (ANI): A new study suggests that women should take calcium and vitamin D supplements after menopause for bone health. An analysis from the major Women's Health Initiative...
View Article27 June 2013 Antares Announces the Issuance of a New US Patent for OTREXUP...
(Source: Antares Pharma Inc) U.S. Patent Number 8,480,631 - Includes Product and Method of Use Claims EWING, NJ, June 27, 2013 - Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has...
View ArticleVitamin D supplements must after menopause
A new study suggests that women should take calcium and vitamin D supplements after menopause for bone health. An analysis from the major Women's Health Initiative (WHI) trial throws weight on the...
View ArticleFDA Approves Baxter’s RIXUBIS as First Recombinant Factor IX Treatment for...
(Source: Baxter International Inc) FDA Approves Baxter's RIXUBIS as First Recombinant Factor IX Treatment for Routine Prophylaxis of Hemophilia B Approval brings patients first new rFIX treatment...
View ArticleVIVUS Announces SPEDRA (avanafil) Approval in Europe (Vivus Inc)
(Source: Vivus Inc) MOUNTAIN VIEW, Calif., June 26, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the "Company") today announced that the European Commission (EC) has adopted the implementing...
View ArticleVIVUS Announces SPEDRA (avanafil) Approval in Europe
MOUNTAIN VIEW, Calif., June 26, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (VVUS) (the "Company") today announced that the European Commission (EC) has adopted the implementing decision...
View ArticleFDA Approves Baxter’s RIXUBIS as First Recombinant Factor IX Treatment for...
Approval brings patients first new rFIX treatment option in more than 15 years DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that the United States Food and...
View ArticleArena Pharmaceuticals Announces BELVIQ™ (lorcaserin HCl) New Drug...
SAN DIEGO, June 26, 2013 -- /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a...
View ArticleArena Pharmaceuticals Announces BELVIQ™ (lorcaserin HCl) New Drug Submission...
SAN DIEGO, June 26, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug...
View ArticleZogenix Launches Improved Migraine Toolbox in Conjunction With National...
SAN DIEGO, June 25, 2013 (GLOBE NEWSWIRE) -- In conjunction with National Migraine Awareness Month and in recognition of the significant unmet needs of migraine sufferers, Zogenix, Inc. (ZGNX) is...
View ArticleACCESS PHARMACEUTICALS ANNOUNCESPOSITIVE TOP-LINE DATA FROM MUGARD™ PHASE IV...
(Source: Access Pharmaceuticals Inc) Met Primary Endpoint of Statistically Significant Reduction in Mouth and Throat Soreness Associated With Oral Mucositis; MuGard Patients Also Had Decreased...
View ArticleAccess Pharmaceuticals Announces Positive Top-Line Data From MuGard™ Phase...
Met Primary Endpoint of Statistically Significant Reduction in Mouth and Throat Soreness Associated With Oral Mucositis; MuGard Patients Also Had Decreased Severity of Oral Mucositis by WHO Score...
View ArticleCalcium and vitamin D supplements improve bone health after menopause
Washington, June 27: A new study suggests that women should take calcium and vitamin D supplements after menopause for bone health. An analysis from the major Women’s Health Initiative (WHI) trial...
View ArticleMedivation and Astellas Initiate Phase 2 Study of Enzalutamide in Breast...
(Source: Medivation Inc) SAN FRANCISCO, CA and TOKYO -- (Marketwired) -- 06/26/13 -- Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced enrollment of the first...
View ArticleNovartis reports new Phase III data showing omalizumab significantly...
(Source: Novartis AG) Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab found to be effective,...
View ArticleLabrys Biologics Presents LBR-101 Late-breaking Data at 2013 International...
SAN MATEO, Calif., June 26, 2013 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for chronic migraine, today announced data from three late-breaking poster...
View ArticleMedivation and Astellas Initiate Phase 2 Study of Enzalutamide in Breast...
SAN FRANCISCO, CA and TOKYO -- (Marketwired) -- 06/26/13 -- Medivation, Inc. (MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced enrollment of the first patient in a global Phase 2 clinical...
View ArticleBiomarker predicts risk of breast cancer recurrence after tamoxifen...
(Source: Massachusetts General Hospital) A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor-positive breast cancer...
View ArticleSprout Pharmaceuticals Confirms Resubmission To FDA Of Flibanserin For...
Phase 3 clinical trial, including >1,000 patients, showed positive results Agency action expected before end of 2013 RALEIGH, N.C., June 26, 2013 /PRNewswire/ -- Sprout Pharmaceuticals, the...
View ArticleWhy I Don't Want To Stay Fertile Forever
I'm reading so many wonderful articles on how to spice up my sex life that I feel remiss in not coming up with some new ideas myself. Yesterday a woman wrote about eating chili peppers off the belly...
View Article